Literature DB >> 18304885

Morphologic changes in branch duct intraductal papillary mucinous neoplasms of the pancreas: a midterm follow-up study.

Pierre-Emmanuel Rautou1, Phillippe Lévy, Marie-Pierre Vullierme, Dermot O'Toole, Anne Couvelard, Dominique Cazals-Hatem, Laurent Palazzo, Alain Aubert, Alain Sauvanet, Pascal Hammel, Olivia Hentic, Vinciane Rebours, Anne-Laure Pelletier, Frédérique Maire, Phillippe Ruszniewski.   

Abstract

BACKGROUND & AIMS: Because there is a low risk of malignancy for intraductal papillary and mucinous neoplasms of the pancreas (IPMNs) confined to branch ducts (BD), patient follow-up evaluation without surgery is possible. The aim of this study was to assess time-related morphologic changes and risk of progress to malignancy in patients with BD IPMN. A prospective design was used in an academic tertiary referral center.
METHODS: All consecutive patients seen from 1999 to 2005 with highly suspected IPMNs confined to BD without criteria suggesting a malignant development (mural nodule, cyst wall thickness >2 mm, BD diameter >30 mm, or main pancreatic duct involvement) were followed up prospectively using computerized tomography, magnetic resonance cholangiopancreatography, and endoscopic ultrasonography.
RESULTS: A total of 121 patients (median age, 63 y) were included. After a median follow-up period of 33 months, no morphologic changes had occurred in 88 patients. The size of the cyst increased in 30 of the 33 remaining patients, and 12 developed criteria suggesting a malignant development. Surgery, performed in 8 of 12 patients, found 4 IPMN-adenomas, 1 borderline-IPMN, and 4 IPMN carcinoma in situ. The 4 remaining patients did not undergo surgery because of severe comorbid conditions in 2, change in reference hospital in 1, and a mural nodule considered being sequelae of previous fine-needle aspiration in 1 patient. The only factor associated with signs suggesting malignant development was an increase in cyst size to more than 5 mm during the follow-up evaluation.
CONCLUSIONS: In patients with IPMNs confined to BD, morphologic changes are rare events, justifying a nonsurgical approach. Careful follow-up evaluation remains necessary, particularly in patients with an increase in BD size.

Entities:  

Mesh:

Year:  2008        PMID: 18304885     DOI: 10.1016/j.cgh.2007.12.021

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  25 in total

1.  Prognosis of cancer with branch duct type IPMN of the pancreas.

Authors:  Nobuhito Ikeuchi; Takao Itoi; Atsushi Sofuni; Fumihide Itokawa; Takayoshi Tsuchiya; Toshio Kurihara; Kentaro Ishii; Shujiro Tsuji; Junko Umeda; Fuminori Moriyasu; Akihiko Tsuchida; Kazuhiko Kasuya
Journal:  World J Gastroenterol       Date:  2010-04-21       Impact factor: 5.742

2.  Active Surveillance Beyond 5 Years Is Required for Presumed Branch-Duct Intraductal Papillary Mucinous Neoplasms Undergoing Non-Operative Management.

Authors:  Stefano Crippa; Raffaele Pezzilli; Massimiliano Bissolati; Gabriele Capurso; Luigi Romano; Maria Paola Brunori; Lucia Calculli; Domenico Tamburrino; Alessandra Piccioli; Giacomo Ruffo; Gianfranco Delle Fave; Massimo Falconi
Journal:  Am J Gastroenterol       Date:  2017-02-28       Impact factor: 10.864

3.  Noninvasive intraductal papillary mucinous neoplasm with para-aortic lymph node metastasis: report of a case.

Authors:  Kazuyuki Nagai; Ryuichiro Doi; Masayuki Koizumi; Toshihiko Masui; Yoshiya Kawaguchi; Akihiko Yoshizawa; Shinji Uemoto
Journal:  Surg Today       Date:  2010-12-30       Impact factor: 2.549

4.  Evaluation of cyst fluid CEA analysis in the diagnosis of mucinous cysts of the pancreas.

Authors:  Satish Nagula; Timothy Kennedy; Mark A Schattner; Murray F Brennan; Hans Gerdes; Arnold J Markowitz; Laura Tang; Peter J Allen
Journal:  J Gastrointest Surg       Date:  2010-07-24       Impact factor: 3.452

5.  Consensus guidelines in the management of branch duct intraductal papillary mucinous neoplasm: a cost-effectiveness analysis.

Authors:  Edward S Huang; G Scott Gazelle; Chin Hur
Journal:  Dig Dis Sci       Date:  2009-10-16       Impact factor: 3.199

6.  Mucin-producing neoplasms of the pancreas: an analysis of distinguishing clinical and epidemiologic characteristics.

Authors:  Stefano Crippa; Carlos Fernández-Del Castillo; Roberto Salvia; Dianne Finkelstein; Claudio Bassi; Ismael Domínguez; Alona Muzikansky; Sarah P Thayer; Massimo Falconi; Mari Mino-Kenudson; Paola Capelli; Gregory Y Lauwers; Stefano Partelli; Paolo Pederzoli; Andrew L Warshaw
Journal:  Clin Gastroenterol Hepatol       Date:  2009-10-14       Impact factor: 11.382

Review 7.  Management of mucin-producing cystic neoplasms of the pancreas.

Authors:  Stefan Fritz; Andrew L Warshaw; Sarah P Thayer
Journal:  Oncologist       Date:  2009-02-11

8.  Podoplanin expression in the cyst wall correlates with the progression of intraductal papillary mucinous neoplasm.

Authors:  Koji Shindo; Shinichi Aishima; Kenoki Ohuchida; Minoru Fujino; Yusuke Mizuuchi; Masami Hattori; Takao Ohtsuka; Shoji Tokunaga; Kazuhiro Mizumoto; Masao Tanaka; Yoshinao Oda
Journal:  Virchows Arch       Date:  2014-07-03       Impact factor: 4.064

9.  Cyst fluid amylase and CEA levels in the differential diagnosis of pancreatic cysts: a single-center experience with histologically proven cysts.

Authors:  Hyoung-Chul Oh; Hyun Kang; William R Brugge
Journal:  Dig Dis Sci       Date:  2014-06-26       Impact factor: 3.199

Review 10.  Malignant potential of intraductal papillary mucinous neoplasms of the pancreas.

Authors:  Yoshiyuki Nakajima; Takatsugu Yamada; Masayuki Sho
Journal:  Surg Today       Date:  2010-08-26       Impact factor: 2.549

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.